Ivan Bergstein
2013
In 2013, Ivan Bergstein earned a total compensation of $2.9M as President and Chief Executive Officer at Stemline Therapeutics, a 292% increase compared to previous year.
Compensation breakdown
| Bonus | $321,145 |
|---|---|
| Non-Equity Incentive Plan | $916,417 |
| Salary | $449,714 |
| Stock Awards | $1,235,306 |
| Total | $2,922,582 |
Bergstein received $1.2M in stock awards, accounting for 42% of the total pay in 2013.
Bergstein also received $321.1K in bonus, $916.4K in non-equity incentive plan and $449.7K in salary.
Rankings
In 2013, Ivan Bergstein's compensation ranked 2,611th out of 12,286 executives tracked by ExecPay. In other words, Bergstein earned more than 78.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,611 out of 12,286 | 79th |
Division Manufacturing | 863 out of 4,612 | 81st |
Major group Chemicals And Allied Products | 229 out of 1,462 | 84th |
Industry group Drugs | 152 out of 1,156 | 87th |
Industry Pharmaceutical Preparations | 129 out of 890 | 86th |
Source: SEC filing on April 8, 2016.
Bergstein's colleagues
We found four more compensation records of executives who worked with Ivan Bergstein at Stemline Therapeutics in 2013.